Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer

In women with metastatic breast cancer (MBC), introduction of the anti-HER2 (human epidermal growth factor receptor-2) directed therapies including trastuzumab, pertuzumab, lapatinib, and/or trastuzumab-DM1 has markedly improved overall survival. However, not all cases of HER2-positive breast tumour...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Yeon Hee, Shin, Hyun-Tae, Jung, Hae Hyun, Choi, Yoon-La, Ahn, TaeJin, Park, Kyunghee, Lee, Aeri, Do, In-Gu, Kim, Ji-Yeon, Ahn, Jin Seok, Park, Woong-Yang, Im, Young-Hyuck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741657/
https://www.ncbi.nlm.nih.gov/pubmed/26397225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741657/
https://www.ncbi.nlm.nih.gov/pubmed/26397225

Ejemplares similares